22 06, 2020

Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor

By |2020-06-22T09:47:31-04:00June 22nd, 2020|Drug Treatment, News, Qinlock|

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.

17 06, 2020

QINLOCK (ripretinib) – aprobado como cuarta línea de tratamiento para GIST

By |2020-06-17T11:29:18-04:00June 17th, 2020|Drug Treatment, Global, News, Qinlock|

La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.

18 05, 2020

FDA Approves QINLOCK (ripretinib) by Deciphera for 4L GIST Patients

By |2020-06-17T11:30:36-04:00May 18th, 2020|Clinical Trials, News|

The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.

14 02, 2020

Priority Review Granted for Ripretinib

By |2020-02-14T09:57:21-05:00February 14th, 2020|Drug Treatment, News|

Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).

14 08, 2019

Deciphera Releases Positive Trial Results for Ripretinib

By |2019-08-14T09:38:14-04:00August 14th, 2019|Drug Treatment, News, Research|

Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]

8 09, 2021

Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock

By |2021-09-08T15:27:33-04:00September 8th, 2021|Advocacy, Global, News, Qinlock|

Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock. 4th line drug approval was approved! GISTer Sarah McGoram shares the news.

30 07, 2021

Actualización realizada por dos prestigiosos especialistas internacionales en GIST

By |2021-07-30T11:03:57-04:00July 30th, 2021|Global, News, Research|

Publicado por Colectivo GIST España - Concluimos el mes dedicado a la concienciación del sarcoma & GIST publicando una actualización del tratamiento para los tumores GIST avanzados.

Need a new search?

If you didn't find what you were looking for, try a new search!

Go to Top